semaglutide 75 Weight Loss Drug Wegovy FDA-Approved for Lowering Heart Disease Risk such as high blood pressure Semaglutide 7.2mg achieved 20.7% weight

Clinical trials demonstrate substantial weight loss: semaglutide (Wegovy) produced approximately 15% average body weight loss, while tirzepatide (Zepbound) produced approximately 20% average weight loss over 72 weeks

Zepbound Pen Clicks Free Zepbound click counter to see how many clicks match your prescribed tirzepatide dose

Wegovy also showed a favorable safety profile

Enter retatrutide (LY3437943), a novel triple hormone receptor agonist developed by Eli Lilly, targeting glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon (GCG) receptors

Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: a scientific statement from the American Heart Association and the American Diabetes Association